March 21st: On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, March 21, 2016

March 21st: On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer

On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer

 (Norgestrel (INN, USAN, BAN, JAN) (brand names Logynon, Nordette, Eugynon, Microgynon, Ovran, Ovranette, Trinordiol, numerous others) is a steroidal progestin that has been used in hormonal contraceptives. It is a mixture of two stereoisomers, dextronorgestrel (CAS# 797-64-8 ) and levonorgestrel (CAS# 797-63-7 ).)

To the Editor:

In their recent article in Journal of Clinical Oncology, Eeles et al1 discuss the adjuvant hormone-replacement therapy (AHT) trial, a randomized trial of 150 patients with ovarian cancer, which included patients across different epithelial cancer histologies and stages who, as a result, were expected to have significantly different outcomes, independent of AHT intervention. The planned duration of replacement as per the protocol was 5 years, but patients stayed on treatment for an average of 1.14 years. Most women were postmenopausal or perimenopausal. Fifty-three of the 72 patients who received therapy in the treatment arm had an estrogen-only preparation, whereas 19 patients received estrogens combined with norgestrel. Doses actually received are not given (suggested doses are listed in the protocol presented in the appendix), which is a significant shortcoming for a study that examines the effect of a pharmacologic intervention.......


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.

Related Articles


Post a Comment

Your comments?